Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
WSD0922-FU and Temozolomide in EGFR Mutant Glioblastoma
NCT07708961Phase 2Recruiting
- Sponsor
- Mayo Clinic
- Start
- Aug 2026
- Primary completion
- Aug 2036
- Countries
- 1
01
Overview
A Phase 2 trial of WSD-0922 in glioblastoma (GBM), sponsored by Mayo Clinic. Started Aug 2026; status: recruiting.
02
Drugs
WSD-0922
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT07708961.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07708961.